EVEREST MEDICINES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.45 HKD | +2.52% |
|
+4.71% | +16.99% |
| 04-25 | Everest Medicines' Loss Widens in 2023 | MT |
| 03-28 | Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 16,708 | 8,413 | 4,747 | 6,088 | 7,233 | - | - |
| Enterprise Value (EV) 1 | 12,248 | 5,924 | 4,367 | 6,088 | 6,546 | 6,477 | 7,258 |
| P/E ratio | -0.86 x | -8.24 x | -18.5 x | - | -11.4 x | -47.2 x | 452 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 155,805 x | 371 x | 48.3 x | 10.7 x | 4.75 x | 2.99 x |
| EV / Revenue | - | 109,710 x | 341 x | 48.3 x | 9.72 x | 4.26 x | 3 x |
| EV / EBITDA | -18.3 x | -5.95 x | -20.4 x | - | -14.5 x | 115 x | 19.8 x |
| EV / FCF | -12.8 x | -7.32 x | - | - | -5.39 x | -20.4 x | -31.7 x |
| FCF Yield | -7.81% | -13.7% | - | - | -18.5% | -4.89% | -3.16% |
| Price to Book | 0.71 x | 1.41 x | 0.81 x | - | 1.84 x | 1.88 x | - |
| Nbr of stocks (in thousands) | 293,222 | 296,715 | 309,246 | 320,493 | 319,835 | - | - |
| Reference price 2 | 56.98 | 28.36 | 15.35 | 19.00 | 22.62 | 22.62 | 22.62 |
| Announcement Date | 22/03/21 | 28/03/22 | 30/03/23 | 27/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.054 | 12.8 | 125.9 | 673.3 | 1,522 | 2,418 |
| EBITDA 1 | - | -668.1 | -995.2 | -214 | - | -450.2 | 56.3 | 366.8 |
| EBIT 1 | - | -688.5 | -1,054 | -256.8 | -932.7 | -649.4 | -155.5 | -96.4 |
| Operating Margin | - | - | -1,952,274.07% | -2,006.25% | -740.67% | -96.44% | -10.22% | -3.99% |
| Earnings before Tax (EBT) 1 | - | -5,658 | -1,009 | -247.3 | -844.5 | -623.5 | -138.2 | 18.82 |
| Net income 1 | -214.5 | -5,658 | -1,009 | -247.3 | -844.5 | -623.5 | -150.6 | 16 |
| Net margin | - | - | -1,867,962.96% | -1,932.03% | -670.57% | -92.6% | -9.89% | 0.66% |
| EPS 2 | -41.04 | -66.29 | -3.440 | -0.8300 | - | -1.986 | -0.4791 | 0.0500 |
| Free Cash Flow 1 | - | -956.4 | -808.8 | - | - | -1,214 | -317 | -229 |
| FCF margin | - | - | -1,497,844.44% | - | - | -180.31% | -20.83% | -9.47% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20/09/20 | 22/03/21 | 28/03/22 | 30/03/23 | 27/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 0.054 | 1.044 | 11.76 | 8.9 | 252.7 | 459.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -406.3 | -653.9 | -639.6 | 382.8 | - | -340.1 | -295.1 |
| Operating Margin | - | - | -1,210,977.78% | -61,269.16% | 3,256.63% | - | -134.57% | -64.19% |
| Earnings before Tax (EBT) | - | - | - | - | 420.8 | - | - | - |
| Net income | - | - | - | - | 420.7 | - | - | - |
| Net margin | - | - | - | - | 3,578.96% | - | - | - |
| EPS 2 | - | -1.310 | -2.130 | -2.260 | 1.430 | - | -1.010 | -0.8300 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 22/03/21 | 30/08/21 | 28/03/22 | 24/08/22 | 30/03/23 | 24/08/23 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | 24.4 |
| Net Cash position 1 | - | 4,460 | 2,489 | 380 | - | 687 | 757 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | 0.0665 x |
| Free Cash Flow 1 | - | -956 | -809 | - | - | -1,214 | -317 | -229 |
| ROE (net income / shareholders' equity) | - | -189% | -15.8% | -4.28% | - | -14% | -5.94% | - |
| ROA (Net income/ Total Assets) | - | -118% | -14.3% | -3.73% | - | -16.5% | -6.7% | - |
| Assets 1 | - | 4,807 | 7,061 | 6,631 | - | 3,779 | 2,247 | - |
| Book Value Per Share 2 | - | 80.20 | 20.10 | 19.00 | - | 12.30 | 12.00 | - |
| Cash Flow per Share 2 | - | -5.530 | -2.490 | -3.880 | - | -2.660 | -0.6100 | - |
| Capex 1 | - | 485 | 79 | 356 | - | 450 | 200 | 200 |
| Capex / Sales | - | - | 146,277.78% | 2,780.59% | - | 66.84% | 13.14% | 8.27% |
| Announcement Date | 20/09/20 | 22/03/21 | 28/03/22 | 30/03/23 | 27/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
22.63
CNY
Average target price
25.92
CNY
Spread / Average Target
+14.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.99% | 975M | |
| -3.45% | 87.17B | |
| +2.76% | 40.1B | |
| -17.19% | 31.38B | |
| +57.86% | 25.12B | |
| -16.40% | 15.59B | |
| -9.12% | 12B | |
| -42.56% | 11.8B | |
| -18.39% | 11.8B | |
| +6.89% | 8.81B |
- Stock Market
- Equities
- 1952 Stock
- Financials Everest Medicines Limited
